Alpha Teknova's Q1 2025: Diverging Views on Macroeconomic Impact and Growth Prospects

Macroeconomic impact on orders and customer behavior, cell and gene therapy customer growth expectations, market stability and growth expectations, and the biotech funding environment and customer demand are the key contradictions discussed in Alpha Teknova's latest 2025Q1 earnings call.



Financial Performance and Revenue Growth:
- Teknova's total revenue for Q1 2025 was $9.8 million, representing a 5% increase year-over-year.
- The growth was driven by a strong performance in catalog products and contributions from the collaboration with Pluristics.

Catalog Product Sales:
- Catalog products revenue increased by low double digits compared to Q1 2024, making up approximately 60% of total revenue.
- This growth was due to an increase in demand across multiple product lines and customer types, including larger one-time orders from select accounts.

Custom Product Revenue Trends:
- Custom product revenue to life science tools and diagnostics customers declined by more than 30%, attributed to a large order delivered to a single customer in Q1 2024.
- Excluding this order, revenue in this segment would have increased high single digits in Q1 2025.

Strategic Collaboration and Product Expansion:
- Teknova signed a collaboration agreement with Pluristics, becoming the exclusive manufacturer and distributor for PluriFreeze cell cryopreservation products in the U.S. and Canada.
- This collaboration expands Teknova's product portfolio and geographic footprint, with potential for additional growth in the long term.